Figure 1
Absolute Contraindications to HiFU.
Figure 2
Outcomes of patients with SDR ≤ 0.40.
Figure 3
Change in CRST hand tremor score after ViM HiFU for Essential Tremor.
Figure 4
Change in CRST C scores after ViM HiFU for Essential Tremor.
Figure 5
Change in CRST C and QUEST scores after ViM HiFU for Essential Tremor.
Figure 6
Change in UPDRS part III scores after HiFU in studies targeting the ViM in Parkinson’s disease.
Figure 7
Change in UPDRS part III scores after HiFU in studies targeting the GPi in Parkinson’s disease.
Figure 8
Change in UPDRS part III scores after HiFU in studies targeting the STN in Parkinson’s disease.
Figure 9
Change in Disability Scores Post-HiFU in Parkinson’s disease, assessed by PDQ-39.
Figure 10
Adverse events after ViM HiFU in Essential Tremor and Parkinson’s Disease.
Figure 11
Adverse events after GPi HiFU in Parkinson’s disease.
Figure 12
Adverse events after STN HiFU in Parkinson’s disease.
Figure 13
Factors influencing decision-making between HiFU or DBS.